TNFRSF17 and plasmacytoma: A total of 101 patients were treated at this dose, all of whom had triple-class-refractory disease after a median of 6 (range 3–15) prior lines of therapy, which included anti-BCMA therapy in 30 (29.7%) patients; 37 (36.6%) had high-risk cytogenetics and 40 (39.6%) had plasmacytomas.